RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert...
TargeGen initiates Phase II clinical trial of topically-applied drug for age-related macular degeneration
News | 07. 30. 2007
TargeGen
TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).
